未找到相关数据
First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study
被引：0
作者：
Andreis, D.
Scandurra, G.
Santini, D.
Gucciardino, C.
La Verde, N. M.
Girelli, S.
Alabiso, I.
Saetta, A.
Atzori, F.
Collova, E.
Ferzi, A.
Gori, S.
Lipari, H.
Saggia, C.
Marcon, I.
Generali, D. G.
机构：
[1] AO Ist Ospitalieri Cremona, UO Multidisciplinare Patol Mammaria, Cremona, Italy
[2] Day Hop, Humanitas Ctr Catanese Oncol, Catania, Italy
[3] Univ Campus Biomed Roma, Dipartimento Med Oncol, Rome, Italy
[4] AO Fatebenefratelli & Oftalm, UO Oncol Med, Milan, Italy
[5] Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy
[6] Fdn Ist San Raffaele D Giglio di Cefalu, UO Oncol, Cefalu, Italy
[7] AOU Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy
[8] Osped Civile Legnano, Legnano, Italy
[9] AO Perugia, Oncol Med, Perugia, Italy
[10] Cannizzaro Hosp, Div Med Oncol, Catania, Italy
[11] AOU Osped Maggiore della Carita, SCDU Oncol, Novara, Italy
[12] AO Osped Circolo, UO Oncol, Varese, Italy
[13] Fdn Macchi, Varese, Italy
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11502
引用
收藏
页数：1
相关论文